Bringing Cancer Genomics to the Clinic

Foundation Medicine has developed FoundationOne^tm, a molecular diagnostics test that analyzes routine clinical specimens for somatic alterations in relevant cancer-related genes. It provides valuable information needed to inform treatment decisions based on an individual patient’s molecular cancer subtype.

Please visit www.FoundationOne.com for complete information about FoundationOne.

Additional information

Making Molecular Information Actionable

The amount of information available for a patient’s molecular profile can be overwhelming—and there is a constant influx of new data to consider. Foundation Medicine provides patient results along with relevant scientific studies, medical evidence and clinical trials to help you assess what treatment options may available for any individual patient on the basis of their molecular cancer subtype.

FoundationOne is designed to capture molecular information for all solid tumor types, therefore alleviating the uncertainty associated with appropriate selection of genomic tests for patients, and subsequent interpretation of multiple sets of information.

One pan-cancer test, relevant somatic alterations

Using DNA extracted from cancer biopsy tissue, our test examines a wide range of specifically targeted cancer-related genes for all potential somatic alterations.

Many molecular tests are set up to identify only pre-determined molecular alterations. Our broad approach, which relevant alterations in cancer related gene, in one test, is made possible by using next-generation sequencing. Although many alterations may be identified, our proprietary analytics specify the small number (average 2-3) of somatic alterations that are reportable and actionable for each patient.

FoundationOne has been optimized and extensively validated to ensure that physician can rely on the results to inform treatment decisions. Some other characteristics of our test include:

Test performance requires a very small amount of cancer tissue such as that typically obtained from surgical resection, core needle biopsy, or fine needle aspirate (FNA).
Uses routine clinical pathological specimens, typically formalin-fixed paraffin embedded (FFPE) tumor tissue.
Captures relevant genomic alterations.
Highly sensitive and specific for alterations within all cancer-related genes examined.
Very high depth of coverage required for cancer sequencing. This is essential to overcome the multiple complexities inherent in cancer genomes (tumor contaminated with non-tumor tissue, tumor heterogeneity, tumor aneuploidy, etc.) in a test that is developed for clinical use.

Accessible, understandable analysis and reporting

FoundationOne makes cancer genomics data accessible and actionable. Evidence levels for using targeted therapies differ widely across gene alterations and tumor types. Even with comprehensive testing results, there is no easy way for physicians to determine which alterations are most important and relevant for therapeutic strategies. Our reporting method distills down the test data into what is relevant to each patient’s tumor by providing individualized, actionable information in a coordinated and easily accessible way.

Commercial Availability

Please visit www.FoundationOne.com for more information or to order FoundationOne.